Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of quinacrine dihydrochloride when
given together with erlotinib hydrochloride and to see how well it works in treating patients
with stage IIIB-IV non-small cell lung cancer. Erlotinib hydrochloride may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as quinacrine dihydrochloride, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. Giving
erlotinib hydrochloride together with quinacrine dihydrochloride may kill more tumor cells